Surprisingly, given that CGN is treated in humans with glucocorticoids, glucocorticoid receptor inhibitors protected against murine CGN by decreasing cellular crescent formation and PEC proliferation/migration, uncovering the direct effects of glucocorticoids on PEC in addition to their well-known immune-suppressive actions [136]. The gene discussed is NR3C1; the disease is childhood gender nonconformity.